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Supplementary Screening Sonography in
Mammographically Dense Breast: 
Pros and Cons
Sonography is an attractive supplement to mammography in breast cancer
screening because it is relatively inexpensive, requires no contrast-medium injec-
tion, is well tolerated by patients, and is widely available for equipment as com-
pared with MRI. Sonography has been especially valuable for women with mam-
mographically dense breast because it has consistently been able to detect a
substantial number of cancers at an early stage. Despite these findings, breast
sonography has known limitations as a screening tool; operator-dependence, the
shortage of skilled operators, the inability to detect microcalcifications, and sub-
stantially higher false-positive rates than mammography. Further study of screen-
ing sonography is still ongoing and is expected to help establish the role of
screening sonography. 
creening is the periodic examination of a population to detect previously
unrecognized disease. The concept that early detection of disease will
reduce mortality is the mainstay of screening. As for breast cancer
screening, mammography has been used as a primary imaging test. The benefit of the
early detection of breast cancer has been shown in randomized controlled trials of
mammography conducted during the past 40 years with a 22% reduction in breast
cancer mortality for women aged 50-69 years who undergo screening (95%
confidence interval, 13-30%) (1). Evaluations of population screening programs in
practice have similarly demonstrated a benefit in women of this age group (2, 3). 
Despite the proven benefits of mammography, results have been less promising for
women with dense breast tissue (4). A dense breast parenchyma may mask some
noncalcified, nondistorted tumors having X-ray attenuation similar to fibroglandular
tissue (5), which increases the difficulty of detecting breast cancer. Mammographic
sensitivity was reported to be as low as 30% to 48% in extremely dense parenchyma
and dense breast itself was found to be a major determinant of interval cancer (6-8).
In addition, dense breast tissue may mimic breast cancer on mammography, which
increases recall rates, reduces specificity, and compromises the benefit of screening in
women with dense breasts (9). In order to improve sensitivity and efficacy of screening
mammography, supplemental screening with sonography has been proposed in
women with mammographically dense breasts and has been evaluated in several
studies since the 1980s (10, 11).
This article will discuss the pros and cons of screening sonography for breast cancer
in mammographically dense breast. 
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Studies for Screening Sonography
The potential use of sonography for breast cancer screen-
ing was first evaluated in the 1980s. Until the early 1990’s,
however, the studies found that sonography was not useful
for screening because of inadequate detection of smaller
cancers and excessive false-positive biopsy rates (11). With
advances in imaging equipment and techniques of sonogra-
phy, in 1995, Gordon and Goldenberg (12) first reported
the ability of sonography to depict nonpalpable,
mammographically occult solid masses, with 3% of these
masses being cancers (prevalence, 0.3%). Since that time,
investigators have reanalyzed the use of screening
sonography in populations of women with dense breasts,
which are summarized in Table 1 (10).
The studies consistently showed that in women with
mammographically dense breast, sonography was able to
detect a substantial number of cancers, with supplemental
cancer detection of 0.3-0.5% by sonography alone. In one
study including women with fatty breasts (13), 11 of 16
cancers diagnosed at sonography were detected in Breast
Imaging Reporting and Data System (BI-RADS) density
three and four breast tissue and the remaining five in BI-
RADS density one and two breast tissue. Moreover, the
data indicated that most breast cancer detected at screen-
ing sonography and previously not detected was at an
early stage (Table 1). In the study by Kaplan (14), all six
cancers were stage 0 or 1 and four of them were smaller
than 1 cm in size. Corsetti et al. (15) reported that the
proportion of early-stage cancer was significantly higher in
the sonography-only detected (65%) than the mammogra-
phy detected cancers (36%, p = 0.001). It is well
established from randomized controlled trials of
mammographic screening that earlier detection of cancer
results in a decrease in mortality which parallels the
reduction in size distribution of cancers depicted and
closely parallels the reduction in rates of node-positive
breast cancer (1).
Pros
As mentioned before, breast density is one of the factors
that points out false-negative findings in mammography.
Furthermore, mammographically dense breast tissue has
been identified as an independent marker strongly associ-
ated with breast cancer risk and in particular with a higher
risk of interval cancer (16). Supplemental screening
imaging such as sonography and MRI can be used to detect
those mammographically occult cancers in dense breast.
Compared with MRI, sonography is relatively inexpensive,
requires no contrast, is well tolerated by patients, and is
widely available for equipment, which is attractive as a
supplement to mammography. Even more, sonographically
guided biopsy of lesions is fast and easy to readily perform
(4). 
The benefit of detection with supplemental sonography
in mammographically occult cancers can increase with
increasing grades of breast density (10, 13, 17). For the
sonography of dense breast, most breast cancers are
relatively hypoechoic within a background of hyperechoic
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Table 1. Results with Screening Breast Sonography 
Breast No. No. No. of Cancers
Cancer Histology N0  Mean Tumor
Study Density a of of (% of Bx, % of Invasive Noninvasive Stage Size 
Exams Bx (%) All Participants) (%) (%) (%) (mm)
Buchberger et al., 
2000 (31) 2-4 08103
b 362 (5) 32 (9, 0.4)0 ND
g NDg ND NDg
Kaplan, 2001 (14) 3-4 01862 051 (3) 06 (12, 0.3) 5 (83) 01 (17) 006 (100) 09.0
Kolb et al., 2002 (8) 2-4 12,193c 320 (3) 33 (10, 0.3) NDh NDh ND NDh
Crystal et al., 2003 (32) 2-4 01517d 038 (3) 07 (18, 0.5) 07 (100) 0 (0) 06 (86) 09.6
Leconte et al., 2003 (13) 1-4 04236e ND 0 16 (ND, 0.4)0 14 (88)0 02 (13) ND 10.9
Corsetti et al., 2008 (15) 3-4 09157 449 (5) 037 (8, 0.4)00 36 (97)0 1 (3) 32 (86) ND
Berg et al., 2008 (19) 2-4 02637e, f ND 0 12 (ND, 0.5)0 11 (92)0 1 (8) 08 (89 i) 12.6
Note.─ a = Density of breast parenchyma on mammogram according to gradation of American College of Radiology BI-RADS protocol on scale of 1-4: 
type 1, breast is almost entirely fat; type 2, there are scattered fibroglandular densities; type 3, breast tissue is heterogeneously dense; and type 4, breast
tissue is extremely dense breast. b = Not included are another 867 examinations performed in women with abnormal mammographic or physical finding.
c = Not included are another 1354 examinations performed in women with abnormal mammographic or physical finding. d = 318 women at high risk of
breast cancer were included, e = Women with abnormal mammographic findings were included. f = All women were at high risk of breast cancer. g = In
published series (31), 35 invasive and 5 noninvasive cancers with mean size of 9.1 mm were detected with sonography in women including symptomatic
group. h = In published series (8), 36 invasive and 1 noninvasive cancers with mean size of 9.9 mm were detected with sonography in women including
group with abnormal mammographic or physical findings. i = 8 of 9 participants with staging
Bx: biopsy, ND: not determined
fibroglandular tissue, which would make lesions more
conspicuous and detectable. In contrast, about one-third of
breast cancers are only mildly hypoechoic with respect to
fat, and these very subtle, mildly hypoechoic or isoechoic
lesions are more likely to be indistinguishable from
surrounding fat in fatty breast (18). 
In the studies of screening sonography in women with
mammographically dense breasts, three to four breast
cancers per 1000 women were detected by sonography
only, and generally at an early stage (Table 1). This
suggests that sonography as an adjunct screening test may
provide further benefit in screening women with dense
breast tissue. However, most studies were performed at
single center and sonographic interpretations might be
biased because readings were not truly blinded to
mammographic findings and in many cases, performed
sonography only when the mammogram was negative
(17). To address those limitations, a prospective multicen-
ter trial of screening sonography for women with interme-
diate and high breast cancer risk (American College of
Radiology Imaging Network [ACRIN] protocol 6666) (19)
was performed. The sequence of performing mammogra-
phy and sonography was randomized to help control the
biases of recruiting women with vague mammographic
abnormalities, and examinations were performed by
radiologists who were masked to results of the other
examination. As a result, sonography was associated with a
55% increase in diagnosing breast cancer compared with
mammography alone. Adding a single screening sonogra-
phy to mammography yielded an additional 4.2 cancers
per 1000 high-risk women. The study provided evidence
for the importance of supplemental breast sonography
screening. Furthermore, these results were consistent and
generalizable across 21 international centers, so that
standardized scanning and interpretive criteria in this trial
proved to be practicable for independent performance and
interpretation (16). 
Cons
Although the addition of a single screening sonography
to mammography increased the diagnostic yield, it also
substantially increased the number of false positives. The
positive predictive value for lesions subjected to biopsy on
the basis of screening sonography findings ranged from 8%
to 18% (mean, 9%) (Table 1). Compared with the positive
predictive value of 25% to 40% recommended for lesions
undergoing biopsy on the basis of screening
mammographic findings, screening sonography may be
expected to result in 2.5 to 4.0 times as many false-positive
biopsy findings per cancer detected (11). Although it is one
of the advantages of sonography that sonographically
guided biopsy is relatively simple and less invasive,
minimizing unnecessary patient anxiety and costs is a
critical goal of any new screening procedure (17). In the
ACRIN protocol 6666 trial, the false-positive rates for
mammography plus sonography (10%) and sonography
alone (8%) were higher than that of mammography alone
(4%), even if the radiologist investigators in this trial were
all specialists in breast imaging who met experience
requirements and completed qualification tasks in sonogra-
phy (19, 20). 
As for cancer characteristics, the vast majority of cancers
seen only on sonography were invasive (94%) because
ductal carcinoma in situ (DCIS) is difficult to see on
sonography (Table 1). Tabar et al. (21) found that
microcalcifications were the predominant mammographic
feature in 85% of cases of high-grade DCIS and 69% of
cases of intermediate- and low-grade DCIS. The interaction
of ultrasound with normal breast tissue produces tiny
bright echoes known as speckle, which simulate faint
microcalcifications and make detection of true microcalci-
fications difficult (22). By projecting ultrasound beams
from several angles, compound imaging will diminish
speckle, but also reduces resolution (11). In contrast,
invasive cancers which often present as hypoechoic masses
on sonography, would be more conspicuous and detectable
within a background of dense fibroglandular tissue (23).
However, it is uncertain whether the detection of DCIS is
required or whether the detection of node-negative
invasive breast cancer is sufficient for a screening test (19).
Breast sonography is limited by operator dependence.
The detection of an abnormality at sonography is
completely dependent on the perception and skill of the
person performing the procedure (24). Unlike most other
radiologic examinations, a lesion not detected while
performing breast sonography will generally not be
documented; and additionally, having representative
normal images is not proof that a mass was not present
(25). This is a limitation of ultrasound in general (24).
Given that sonography is operator-dependent, intra- or
interoperator variability is to be expected in screening
sonography. Although Berg et al. (25) found substantial
reliability for reporting lesion size, location, and key
features, as was moderate agreement for lesion manage-
ment with whole-breast sonography, participating examin-
ers were physicians specialized and highly skilled in breast
sonography and they performed sonography using a
standardized scanning protocol and interpretive criteria.
Conversely, without the implementation of a standardized
technique and interpretation, as well as training and
qualification for screening sonography, the result in general
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practice could vary from the aforementioned study.
Difficulty with reproducibility potentially limits the ability
to accurately monitor the sonography-only masses that are
thought to probably be benign and suitable for surveillance
with follow-up examinations (24).
Screening sonography is so time-consuming and would
require a much larger number of qualified breast radiolo-
gists than currently available. In the ACRIN protocol 6666
trial (19), a breast screening sonography takes an average
of 19 minutes of physician time. In comparison, breast
radiologists will complete less than three screening
sonographic studies per hour. However, a breast radiolo-
gist, if involved in batch reading of screening
mammograms, will read about 50 studies per hour (26).
Moreover, the time of 19 minutes does not include
comparison to prior studies, discussion of results with
patients, nor the creation of a final report (19). At this
time, however, there is insufficient evidence to address the
efficacy of technologist-performed screening sonography
(27). Furthermore, many incidental lesions will be detected
during screening sonography which require a biopsy or
follow-up. Whether the additional cost of screening with
sonography will be cost-effective should be determined
(28).
Further Researches
To overcome the lack of uniformity or reproducibility
and the shortage of qualified personnel limiting the wide
implementation of screening sonography, automated
whole breast sonography may be helpful. In a study of
automated whole breast sonography added to mammogra-
phy in asymptomatic women with dense breasts and/or at
an elevated risk of breast cancer (29), adding automated
whole breast sonography to mammography yielded an
additional 3.6 cancers per 1000. This finding is consistent
to supplemental yield findings of earlier studies using hand-
held sonography (2.7 to 4.6 per 1000), and moreover,
87% of cancer detections added by automated whole
breast sonography were found in 68% of studies in women
with dense breasts. However, clinical validation by further
studies is needed to be implemented in breast cancer
screening.
In general, the rate of cancers detected in patients
screened for the first time (prevalent cancers) should be
much higher than in a population that has been screened
previously (incidental cancers). Thus, knowledge of the
proportion of initial screening examinations to follow-up
screening examinations can be extremely useful in
interpreting the results (30). Although Kolb et al. (8)
performed multiple rounds of screening sonography, they
did not distinguish results from each round. The other
series to date reported on a single prevalence screen; an
estimate of the yield from annual screening sonography is
not available. Compared with mammographic screening,
the cancer detection rate of sonographic screening (2.7-
4.6/1000 exams) was lower than would be expected from
a mammographic prevalence screen (6-10/1000 first-time
exams), but was comparable to a mammographic incidence
screen (2-4/1000 follow-up exams). The reason for similar
results of screening sonography to mammographic
incidence screening could be attributed to the fact that
many women in these studies probably had several
previous mammographic screenings but no previous
sonographic screening. Moreover, factors favoring
sonographic detection are different from those favoring
mammography detection (11). The data on incident
screens from subsequent rounds in the ACRIN protocol
6666 trial will be forthcoming and will be important for
determining stage distribution of breast cancers in
subsequent rounds of screening with mammography plus
sonography in this study (1, 27). 
In conclusion, although mammography remains the
mainstay of breast cancer screening, screening sonography
in women with mammographically dense breast has been
reported consistently to detect a substantial number of
sonography-only cancers at an early stage. However,
further study is needed to validate and implement the
screening sonography in clinical practice, which is ongoing.
Radiologists need to be familiar with the pros and cons of
screening sonography and also be able to frame a proper
concept of sonography for breast cancer screening.
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